PeterSwannMD
Family Medicine • Eden Prairie, MNSports Medicine (Non-Surgical), Occupational Medicine
Co-Founder and Chief Medical Officer ISOThrive, Inc.
Dr. Swann is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
8387 Townsend Dr
Eden Prairie, MN 55344Phone+1 925-899-8366
Summary
- Dr. Peter Swann is a Family Physician in Eden Prairie, MN. He is the Co-Founder and Chief Medical Officer at ISOTHrive Inc., a mid-stage pharmaceutical company pioneering microbiome manipulation for disease prevention and treatment. He received his medical degree from Tufts University School of Medicine and has been in practice 29 years. He specializes in microbiome science, sports medicine (non-surgical) and occupational medicine and is experienced in gastroesophageal reflux, irritable bowel syndrome, complementary and integrative medicine, occupational medicine, and environmental health. He has 3 publications.
Education & Training
Silas B Hays Army Community HospitalResidency, Family Medicine, 1988 - 1991
Tufts University School of MedicineClass of 1988- Dartmouth CollegeB.A., Neuroscience, 1979 - 1983
Certifications & Licensure
CA State Medical License 1990 - 2026
MN State Medical License 2018 - 2025
UT State Medical License 2019 - 2024
AZ State Medical License 2012 - 2021
WI State Medical License 2019 - 2021
NV State Medical License 2012 - 2019
LA State Medical License 1991 - 1995- American Board of Family Medicine Family Medicine
- National Board of Physicians and Surgeons Family Medicine
Awards, Honors, & Recognition
- Fellow of the American Academy of Family Physicians AAFP
- Fellow of the American College of Occupational and Environmental Medicine ACOEM
Clinical Trials
- Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERD Start of enrollment: 2023 Mar 03
- Tolerability Study of Panosyl-Isomaltooligosaccharides (PIMO) and a Placebo in Subjects With Heartburn Start of enrollment: 2022 Feb 10
- Tolerability Study of Panosyl Isomaltooligosaccharides (PIMO), in Subjects With Chronic Idiopathic Constipation (CIC) Start of enrollment: 2021 Sep 23
Publications & Presentations
Journal Articles
- Improvement in Gastroesophageal Reflux Symptoms From a Food-grade Maltosyl-isomaltooligosaccharide Soluble Fiber Supplement: A Case SeriesSelling J, Swann P, Madsen LR II, Oswald J, Integr Med (Encinitas), 10/17/2018
- Isomaltooligosaccharide-Based Food IngredientsMadsen LR II, Stanley SE, Swann P and Oswald J, J Food Sci, 2017
Abstracts/Posters
- GERD: MOVING FROM A TO B? REDEFINING THE PARADIGM FROM ACID TO BACTERIA: A NOVEL PREBIOTIC MICROBIOME THERAPEUTIC (ISOT-101), MALTOSYL-ISOMALTO-OLIGOSACCHARIDES (MIMO)...Selling, John ; Swann, Peter ; Madsen, Lee R. ; Oswald, Jack ; Johnson, David A, Digestive Disease Week 2021, Virtual, 5/21/2021
Press Mentions
Good for Your Gut: The Digest’s 2019 Multi-Slide Guide to ISOThriveMay 13th, 2019
Study Shows ISOThrive Prebiotic Feed Additive Substantially Reduces Antibiotic-Resistant Salmonella “Super Bugs” in ChickensNovember 15th, 2016
Professional Memberships
- Fellow
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
